uploads/2018/12/Sangamo.png

A Financial Overview of Sangamo Therapeutics in December 2018

By

Updated

Revenue trends

In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million. In this period, Sangamo Therapeutics generated revenues of $57.3 million from collaborations and $237,000 from research grants.

In the third quarter, the company reported net revenues of $23.6 million, reflecting ~99% YoY growth. In the third quarter, the company reported collaboration revenues of $23.5 million and revenues from research grants of $24,000.

Wall Street analysts estimate that Sangamo Therapeutics will generate revenues of $22.43 million in the fourth quarter of 2018. Analysts also estimate that the company is expected to report net revenues of around $79.8 million in fiscal 2018.

The revenue growth of Sangamo Therapeutics could boost the Invesco Dynamic Biotechnology & Genome ETF (PBE). Sangamo Therapeutics makes up about ~2.58% of PBE’s total portfolio holding.

In the third quarter, Crispr Therapeutics (CRSP) and bluebird bio (BLUE), Sangamo Therapeutics’ peers in the biopharmaceuticals market, generated revenues of $0.56 million and $11.53 million, reflecting a ~76% YoY decline and ~49.5% YoY growth.

Wall Street analysts estimate that Crispr Therapeutics and bluebird bio will generate revenues of $5.6 million and $43.20 million, respectively, in fiscal 2018.

Article continues below advertisement

Sangamo acquired Txcell

In December 2018, Sangamo Therapeutics completed the acquisition of TxCell. TxCell is no longer listed in French stock markets. TxCell’s leading product is CAR-Treg, an investigational product candidate that can be utilized for a solid organ transplant. Sangamo Therapeutics anticipates submitting a clinical trial authorization application in Europe in 2019.

Advertisement

More From Market Realist